Literature DB >> 24373506

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

Wen-Yu Chuang1, Philipp Ströbel2, Anna-Lena Bohlender-Willke3, Peter Rieckmann4, Wilfred Nix5, Berthold Schalke6, Ralf Gold7, Andreas Opitz8, Erdwine Klinker9, Masayoshi Inoue10, Hans Konrad Müller-Hermelink11, Güher Saruhan-Direskeneli12, Peter Bugert13, Nick Willcox14, Alexander Marx15.   

Abstract

Late-onset myasthenia gravis (LOMG) has become the largest MG subgroup, but the underlying pathogenetic mechanisms remain mysterious. Among the few etiological clues are the almost unique serologic parallels between LOMG and thymoma-associated MG (TAMG), notably autoantibodies against acetylcholine receptors, titin, ryanodine receptor, type I interferons or IL-12. This is why we checked LOMG patients for two further peculiar features of TAMG - its associations with the CTLA4(high/gain-of-function) +49A/A genotype and with increased thymic export of naïve T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas. We analyzed genomic DNA from 116 Caucasian LOMG patients for CTLA4 alleles by PCR/restriction fragment length polymorphism, and blood mononuclear cells for recent thymic emigrants by quantitative PCR for T cell receptor excision circles. In sharp contrast with TAMG, we now find that: i) CTLA4(low) +49G(+) genotypes were more frequent (p = 0.0029) among the 69 LOMG patients with age at onset ≥60 years compared with 172 healthy controls; ii) thymic export of naïve T cells from the non-neoplastic thymuses of 36 LOMG patients was lower (p = 0.0058) at diagnosis than in 77 age-matched controls. These new findings are important because they suggest distinct initiating mechanisms in TAMG and LOMG and hint at aberrant immuno-regulation in the periphery in LOMG. We therefore propose alternate defects in central thymic or peripheral tolerance induction in TAMG and LOMG converging on similar final outcomes. In addition, our data support a 60-year-threshold for onset of 'true LOMG' and an LOMG/early-onset MG overlapping group of patients between 40 and 60.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AIRE; CTLA4; Myasthenia gravis; Myoid cells; TRECs; Thymus

Mesh:

Substances:

Year:  2013        PMID: 24373506     DOI: 10.1016/j.jaut.2013.12.006

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  [True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children].

Authors:  C-A Weis; B Märkl; T Schuster; K Vollert; P Ströbel; A Marx
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 3.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

4.  Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.

Authors:  Michael F Seldin; Omar K Alkhairy; Annette T Lee; Janine A Lamb; Jon Sussman; Ritva Pirskanen-Matell; Fredrik Piehl; Jan J G M Verschuuren; Anna Kostera-Pruszczyk; Piotr Szczudlik; David McKee; Angelina H Maniaol; Hanne F Harbo; Benedicte A Lie; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Peter K Gregersen; Lennart Hammarstrom
Journal:  Mol Med       Date:  2015-11-10       Impact factor: 6.354

5.  The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.

Authors:  Gizem A Kaya; Ayse N Coşkun; Vuslat Yılmaz; Piraye Oflazer; Yeşim Gülsen-Parman; Fikret Aysal; Rian Disci; Haner Direskeneli; Alexander Marx; Feza Deymeer; Güher Saruhan-Direskeneli
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

Review 6.  Thymus and autoimmunity.

Authors:  Alexander Marx; Yosuke Yamada; Katja Simon-Keller; Berthold Schalke; Nick Willcox; Philipp Ströbel; Cleo-Aron Weis
Journal:  Semin Immunopathol       Date:  2021-02-03       Impact factor: 9.623

7.  CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population.

Authors:  Liang Sun; Yunxiao Meng; Yanchen Xie; Hua Zhang; Zheng Zhang; Xiaoxia Wang; Bin Jiang; Wei Li; Yao Li; Ze Yang
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

Review 8.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.